Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ABOS vs ASTL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ASTL Captures Overall Composite Edge (31.5 SELL vs 49.5 HOLD), While ABOS Leads 4–2 on Growth & Valuation Pillars

ASTL Overall Winner 6-Pillar Tally: ABOS 4 – 2 ASTL Matrix Metrics: ABOS 4 – 6 ASTL

As of Nov 17, 2026, Algoma Steel Group Inc. Common Shares (ASTL) captures the overall head-to-head institutional edge over Acumen Pharmaceuticals, Inc. (ABOS) on higher Unified Composite conviction (31.5/100 SELL vs. 49.5/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, R&D & Supply-Chain Moat), while ABOS wins 4–2 across the 6-pillar growth and valuation breakdown. ABOS trades at $0.21 (N/M Forward P/E, 0.0% operating margin) versus ASTL at $5.08 (9.1x Forward P/E, -63.3% operating margin).

  • Composite vs. Pillar Nuance: While ABOS currently prints a higher short-term Unified Composite Score (49.5/100 HOLD vs. ASTL 31.5/100 SELL), ASTL captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-63.3% vs. 0.0% operating margin) and revenue trajectory (-52.4% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: ABOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.7); meanwhile ASTL trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABOS vs ASTL
ABOS NASDAQ
Acumen Pharmaceuticals, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.21
-0.97% 1D
Market Cap $15.5M
TTM Revenue $329,000
Forward P/E N/M
Beta / 30D Vol 2.63β · 327% Vol
Unified Composite Score
49.5 / 100 HOLD
Tech 55.0 Fund 58.0 Flow 68.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -31.8%), weak momentum, RSI 22
RSI-14: 21.7 · SMA20: $0.91 · SMA50: $1.73
ASTL NASDAQ Head-to-Head Winner
Algoma Steel Group Inc. Common Shares
Steel Works, Blast Furnaces & Rolling Mills (Coke Ovens)
$5.08
-5.13% 1D
Market Cap $575.9M
TTM Revenue $1.27B
Forward P/E 9.1x
Beta / 30D Vol 1.65β · 66% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 8.0 Fund 35.0 Flow 57.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.5% over 20 days), RSI 51
RSI-14: 51.2 · SMA20: $5.15 · SMA50: $4.61

6-Pillar Scorecard Institutional Category Breakdown (ABOS 4 – 2 ASTL)

Columns: Metric · ABOS · ASTL
1. Valuation Multiples ASTL
Forward P/E N/M 9.1x
Trailing P/E N/M 9.1x
PEG Ratio N/M N/M
EV / Revenue N/M 1.1x
2. Growth & Scale ABOS
Revenue Growth (YoY) +0.0% -52.4%
Earnings Growth (YoY) +0.0% -93.0%
TTM Revenue (USD) $329,000 $1.27B
Market Cap $15.5M $575.9M
3. Profitability & Quality ABOS
Gross Margin N/A -53.2%
Operating Margin 0.0% -63.3%
Net Profit Margin 0.0% -59.1%
Return on Equity (ROE) -162.7% -139.8%
4. Balance Sheet & Cash Flow ABOS
Cash Generation (TTM) -$105M EBITDA -$164M
Cash Flow Margin N/A -12.9%
Net Cash / Leverage $27M Net Cash $794M Net Debt (4.78x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABOS
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 232.4% (41st %ile) 70.9% (15th %ile)
Put/Call OI Skew N/A 0.08x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat ASTL
OpEx & R&D Intensity N/A 10.1% of Rev ($128M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Steel Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABOS (4) vs ASTL (6)
Institutional Metric ABOS ASTL Criterion Row Edge
Market Capitalization
Scale
$15.5M $575.9M Larger Scale ASTL
Trailing P/E Ratio
Valuation
N/M 9.1x Lower Multiple ASTL
Forward P/E Ratio
Valuation
N/M 9.1x Lower Multiple ASTL
Revenue Growth (YoY)
Growth
+0.0% -52.4% Higher Growth ABOS
Operating Margin (TTM)
Profitability
0.0% -63.3% Higher Margin ABOS
Net Profit Margin
Profitability
0.0% -59.1% Higher Margin ABOS
Return on Equity (ROE)
Capital Efficiency
-162.7% -139.8% Higher ROE ASTL
52-Week Range Position
Momentum
1% ($0–$4) 70% ($3–$6) Stronger Trend ASTL
Beta / 30D Volatility
Risk Regime
2.63β · 327% Vol 1.65β · 66% Vol Lower Realized Risk ASTL
Unified Institutional Score
Composite Signal
49.5 / 100 (HOLD) 31.5 / 100 (SELL) Higher Composite ABOS
Trailing 12M Revenue (USD)
Operating Scale
$329,000 $1.27B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -53.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$105M EBITDA ($27M Net Cash) -$164M ($794M Net Debt (4.78x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ASTL +111.04 pp
ABOS: -87.92% · ASTL: +23.12%
3M Horizon ASTL +99.37 pp
ABOS: -93.21% · ASTL: +6.16%
6M Horizon ASTL +88.31 pp
ABOS: -90.14% · ASTL: -1.83%
1Y Horizon ASTL +129.68 pp
ABOS: -87.64% · ASTL: +42.04%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABOS vs ASTL. Trailing 12-month operating profitability (ABOS 0.0% vs ASTL -63.3%) and valuation multiples (ABOS N/M vs ASTL 9.1x Forward P/E) are benchmarked directly in Pillar 4 below.

ABOS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$329,000
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-162.7% · N/M
ASTL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.27B
Gross Margin-53.2%
Op. Margin-63.3%
ROE / Fwd P/E-139.8% · 9.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABOS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 232.4%
IV Percentile 41st %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ABOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ASTL CONSOLIDATION
118d in phase · OBV DISTRIBUTION
Current IV 70.9%
IV Percentile 15th %ile
Put/Call OI Skew 0.08x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ASTL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABOS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ASTL Moat Profile Cyclical / Execution-Driven Positioning
Steel Operator
Competes within the Steel value chain with $575.9M market capitalization and -63.3% operating margin.
OpEx & R&D Reinvestment 10.1% of Rev ($128M)
90D Engineering Disclosures 0 Published

Investor FAQ ABOS vs ASTL Key Questions & Quantitative Answers

As of Nov 17, 2026, Algoma Steel Group Inc. Common Shares (ASTL) captures the overall head-to-head institutional edge over Acumen Pharmaceuticals, Inc. (ABOS) on higher Unified Composite conviction (31.5/100 SELL vs. 49.5/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, R&D & Supply-Chain Moat), while ABOS wins 4–2 across the 6-pillar growth and valuation breakdown. ABOS trades at $0.21 (N/M Forward P/E, 0.0% operating margin) versus ASTL at $5.08 (9.1x Forward P/E, -63.3% operating margin). Composite vs. Pillar Nuance: While ABOS currently prints a higher short-term Unified Composite Score (49.5/100 HOLD vs. ASTL 31.5/100 SELL), ASTL captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-63.3% vs. 0.0% operating margin) and revenue trajectory (-52.4% vs. +0.0% YoY). Technical & Structure Timing Caution: ABOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.7); meanwhile ASTL trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABOS leads the Growth & Scale pillar: ABOS posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $329,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with ASTL at -52.4% YoY revenue growth and -93.0% YoY earnings growth on $1.27B TTM revenue (-53.2% gross margin, -63.3% operating margin). On trailing 12-month operating scale, ABOS generates $329,000 in USD-normalized revenue versus $1.27B for ASTL. In operating R&D and SG&A reinvestment, ABOS deploys N/A (0 90-day corporate R&D disclosures) versus 10.1% of Rev ($128M) (0 disclosures) for ASTL.

ASTL screens cheaper on headline valuation multiples. ABOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas ASTL trades at 9.1x Forward P/E, 9.1x Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-12.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABOS (-162.7% ROE) versus ASTL (-139.8% ROE) capital efficiency.

In options market volatility and institutional positioning, ABOS carries 232.4% implied volatility (41st %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.63β · 327% Vol realized risk). By comparison, ASTL carries 70.9% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.65β · 66% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.